<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282799</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17080453</org_study_id>
    <nct_id>NCT03282799</nct_id>
  </id_info>
  <brief_title>Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic Evaluation of Etonogestrel Dose Escalation With Efavirenz-based Antiretroviral Therapy in HIV-infected Ugandan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catherine Chappell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Disease Institute, Kampala, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the frequency of ovulation and cervical mucus quality of
      HIV-infected women on efavirenz (EFV)-based antiretroviral therapy (ART) using either a
      single etonogestrel (ENG) implant or two ENG implants for at least one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to drug-drug interactions between efavirenz (EFV) and progestins, HIV-infected women on
      EFV-based antiretroviral therapy (ART) and using the etonogestrel implant have significantly
      lower systemic ENG concentrations than HIV-infected women not on ART. This finding has raised
      concerns regarding the contraceptive efficacy of the ENG implant for women on EFV-based ART
      and clinical studies have an increased rate of pregnancies for women on EFV-based ART and
      using a contraceptive implant. This study a randomized, open-label, longitudinal
      pharmacodynamic study to compare frequency of ovulation between a control group of
      HIV-infected women on efavirenz-based antiretroviral therapy receiving standard dose
      etonogestrel (ENG) implant and a treatment group receiving increased dose ENG implant. The
      overall goal is to assess the pharmacodynamic significance of the known drug-drug interaction
      between EFV and ENG and to determine if the increased dose will overcome this interaction.
      Overall, this study will improve long-acting reversible contraceptive treatment options for
      women living with HIV and prevent unintended pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation</measure>
    <time_frame>weekly at months 3, 6, and 12</time_frame>
    <description>Ovulation evaluated by endogenous progesterone concentrations of &gt;3ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cervical mucus quality</measure>
    <time_frame>weekly at months 3, 6, and 12</time_frame>
    <description>World Health Organization Cervical Mucus Scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Etonogestrel pharmacokinetics</measure>
    <time_frame>Week 1, 4, 12, 24, 36, and 48</time_frame>
    <description>Etonogestrel serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to months 12</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Standard Dose Etonogestrel Implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single 68 mg etonogestrel implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Increased Dose Etonogestrel Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 68 mg (136 mg total) etonogestrel implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etonogestrel implant</intervention_name>
    <description>The etonogestrel implant is an contraceptive implant that is placed into the upper arm.</description>
    <arm_group_label>Standard Dose Etonogestrel Implant</arm_group_label>
    <arm_group_label>Increased Dose Etonogestrel Implant</arm_group_label>
    <other_name>Nexplanon</other_name>
    <other_name>Implanon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document indicating that
             the participant has been informed of all pertinent aspects of the study.

          2. Participants who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

          3. Women age 18 years to 40 years

          4. Diagnosed with HIV infection

          5. Medically eligible for the ENG subdermal implant as a contraceptive method based on
             the WHO Medical Eligibility Criteria for Contraceptive Use20

          6. Receiving EFV-based ART for a minimum of 3 months prior to screening

          7. Must agree to have concurrent highly effective non-hormonal contraception with a
             copper IUD, if not previously medically sterilized.

          8. Participants must report regular menses (bleeding for 4-8 days at 21 to 35 day
             intervals) for the preceding 2 month

          9. Participants must have a negative urine pregnancy test at entry and report no
             unprotected sex since the last menstrual period or in the last two weeks.

        Exclusion Criteria:

          1. HIV RNA &gt; 50 copies/mL at screening visit

          2. Serum hemoglobin &lt; 10.0 g/dl

          3. Elevations in serum levels of alanine transaminase (ALT) above 5 times the upper limit
             of normal

          4. Elevations in serum creatinine above 2.5 times the upper limit of normal

          5. Use of drugs known to be contraindicated with ENG or EFV within 30 days of study
             entry. Due to the dynamic nature of drug interactions related to ART, the study team
             will review all concomitant medications at screening based on the US Department of
             Health and Human Services drug interaction table45 and the ENG implant product
             labeling15.

          6. Currently pregnant or postpartum &lt;30 days at study entry.

          7. Breastfeeding women within 6 months of delivery.

          8. Use of hormonal contraception in the preceding 3 months prior to entry

          9. Participants determined to be ineligible for IUD placement by the WHO Medical
             Eligibility Criteria for Contraceptive Use46

         10. Patients with a history of hypersensitivity to ENG implant, undiagnosed vaginal
             bleeding, diagnosed or suspected sex hormone dependent neoplasia, benign or malignant
             liver tumor, or thromboembolic disease.

         11. Presence of any active clinically significant disease or life-threatening disease
             that, in the investigator's opinion, would compromise the subject's safety or outcome
             of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine A Chappell, MD MSc</last_name>
    <phone>412-641-1403</phone>
    <email>chappellca@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dionne Best</last_name>
    <phone>412-641-5496</phone>
    <email>bestdm@mail.magee.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious Disease Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohammed Lamorde, MRCP PhD</last_name>
      <phone>+256414307291</phone>
      <email>mlamorde@idi.co.ug</email>
    </contact>
    <contact_backup>
      <last_name>Shadia Nakalema, MBChB, DTMH</last_name>
      <phone>+256414307238</phone>
      <email>snakalema@idi.co.ug</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine A Chappell, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Lamorde, MRCP PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kim Scarsi, PharmD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Catherine Chappell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>etonogestrel</keyword>
  <keyword>efavirenz</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

